Medical breakthroughs using the mRNA technology that powered rapid COVID-19 vaccine development are demonstrating significant progress against aggressive cancers, including melanoma and previously untreatable pancreatic and brain tumors.
These promising developments in cancer vaccine research – considered among the most rapidly expanding areas of cancer treatment studies – are emerging even as federal officials have sent mixed messages regarding the technology’s value and safety profile.
Over 130 research presentations focusing on these therapeutic approaches were shared at this month’s American Society of Clinical Oncology conference held in Chicago.
Leading the field are Moderna and Merck, whose combined treatment using a potent immunotherapy medication alongside an individualized mRNA cancer vaccine has successfully prevented melanoma recurrence for five years – marking a significant achievement in developing customized vaccines that teach immune systems to target cancer cells.
Both companies are currently conducting mRNA-based therapy trials across nine major and intermediate-sized studies targeting lung, kidney, bladder and pancreatic cancers, with potential preliminary data from their comprehensive melanoma confirmation trial expected within the year.
Meanwhile, extensive early-stage research conducted at academic institutions and medical facilities has advanced to development phases at pharmaceutical companies such as Roche and BioNTech.
Vision Research Reports, a market analysis firm, projects that the personalized cancer vaccine market, primarily driven by mRNA technology, could generate $8.5 billion in annual revenue by 2034.
Traditional vaccines for infectious diseases work by training immune systems to identify and combat viruses, providing extended protection.
“That principle can now be applied to cancer, and that’s a big advance,” stated Merck Chief Medical Officer Eliav Barr.
These developments occur despite the U.S. Department of Health and Human Services, under the leadership of anti-vaccine activist Robert F. Kennedy Jr., eliminating $500 million from mRNA vaccine initiatives. Kennedy has challenged mRNA vaccine safety and effectiveness without supporting evidence while making inflated statements regarding adverse effects.
However, the National Cancer Institute continues working with the Foundation for the National Institutes of Health through a $200 million public-private collaboration funding trials for promising cancer vaccines, including mRNA-based options.
Scientists warn that separating mRNA research into isolated categories could hinder progress in a technology that has been safely administered to over 700 million individuals during the COVID pandemic.
“We have to be able to innovate around technologies that are going to improve healthcare for all,” explained Dr. Elias Sayour, who leads an RNA engineering laboratory at the University of Florida and advises the NCI’s cancer vaccine initiative. “If we don’t do it, other countries will.”
HHS did not provide a response to requests for comment.
Ten years ago, Dr. Vinod Balachandran from Memorial Sloan Kettering Cancer Center was among pioneering researchers who recognized mRNA’s potential for treating even the most lethal cancers.
He observed that occasionally, certain patients managed to survive pancreatic cancer, a condition researchers thought remained hidden from immune system detection.
Research showed that in these instances, patients’ immune systems successfully identified and attacked their tumors. The challenge was determining how to make this occurrence more frequent.
Balachandran theorized that mRNA, which can be produced rapidly, could create personalized vaccines based on unique mutations found exclusively in patients’ tumors following surgical removal.
A phase 1 study involving 16 patients began in December 2019, testing a combination of chemotherapy, Roche’s immunotherapy Tecentriq, and a custom-made mRNA vaccine from BioNTech that targeted mutated proteins specific to individual patients’ tumors.
During April’s American Association for Cancer Research meeting, Balachandran reported that among eight pancreatic cancer patients whose immune systems responded to the vaccine, seven remained alive up to six years following treatment.
A 260-patient international phase 2 trial is currently ongoing to validate these findings.
“What a breakthrough it would be if mRNA was the technology that finally was able to achieve an immune response that was clinically meaningful,” commented Dr. Robert Vonderheide, director of Penn Medicine’s Abramson Cancer Center and AACR’s president-elect.
Messenger ribonucleic acid, or mRNA, exists naturally within every body cell. Its function involves transporting genetic instructions from cell nuclei to cellular components that produce specific proteins.
University of Florida’s Sayour describes mRNA as the human body’s software. It can be reprogrammed for various functions, including creating proteins that train immune systems to attack infectious agents or abnormal cancer cells, he explained.
This research is being conducted at Mount Sinai, where Brian Brown, director of the Icahn Genomics Institute, has created a method for designing lipid nanoparticles – the fatty capsules that transport mRNA into cells – to control their destination within the body.
Research published in Nature Biotechnology during April indicates mRNA could be enhanced or reduced to strengthen immune responses or decrease harmful reactions, potentially leading to more effective cancer treatments or novel approaches for autoimmune diseases.
Sayour has created a vaccine involving injections of lipid nanoparticle clusters into glioblastoma patients, rather than the single nanoparticle approach used in COVID vaccines.
Administered through intravenous delivery, the goal is to rapidly stimulate immune systems to combat the aggressive brain cancer, which has a five-year survival rate below 7%.
Targeting a cancer like glioblastoma represents a significant challenge for any vaccine, Sayour acknowledged. However, he stated, “if it can cure or even make a dent in glioblastoma, the implications for all forms of human cancer, in my mind, are extraordinary.”
